½ÃÀ庸°í¼­
»óǰÄÚµå
1699463

¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå : µ¿¹° À¯Çüº°, ÀûÀÀÁõº°, Ä¡·á¹ýº°, À¯Åë ä³Îº°, Áö¿ªº°

Companion Animal Arthritis Market, By Animal Type, By Indication, By Treatment, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀº 2025³â¿¡´Â 46¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â±îÁö´Â 78¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 7.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 46¾ï 7,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 7.60% 2032³â ±Ý¾× ¿¹Ãø 78¾ï ´Þ·¯
µµÇ¥. ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå Á¡À¯À²(%), Áö¿ªº°(2025³â)
Companion Animal Arthritis Market-IMG1

°ñ°üÀý¿°(OA)Àº °³¿Í °í¾çÀ̰¡ ÈçÈ÷ °É¸®´Â ÁúȯÀÔ´Ï´Ù. Àú¾Ç¼ºµµÀÇ ¿°Áõ¼º ÁøÇ༺ ÅðÇ༺ °üÀý ÁúȯÀÎ °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. °ñ°üÀý¿°Àº ¿¬°ñÇÏ °ñ´ë»ç º¯È­, °ñ±Ø, Ȱ¸· ¿°Áõ¿¡ µû¸¥ °üÀý ¿¬°ñÀÇ ÅðÇà°ú ¼öº¹ À̻󿡼­ ºñ·ÔµË´Ï´Ù. ¹Ý·Áµ¿¹°¿¡¼­´Â °üÀýÀÌ¿ÏÁõ, °ñ¿¬°ñÁõ, ¿Ü»ó µî°ú °°Àº ±âÃÊÀûÀÎ À̻󿡼­ ÀÌÂ÷ÀûÀ¸·Î OA°¡ ¹ß»ýÇÏ´Â °æ¿ì°¡ ´ëºÎºÐÀÔ´Ï´Ù. ÀÌ´Â °üÀý³¶ÀÇ ¼¶À¯È­¿Í °ñ¸·ÀÇ ¹ÝÀÀÀ» Æ÷ÇÔÇÑ º´¸®ÇÐÀû °úÁ¤À¸·Î º¸Çà°ú ¿îµ¿ ¹üÀ§ÀÇ º¯È­·Î À̾îÁý´Ï´Ù. ±× °á°ú ±Ù°ñ°Ý°è¿Í ÀÌÂ÷ÀûÀÎ °üÀý ¾ÈÁ¤ÀåºñÀÇ ÀúÇϰ¡ ÀϾ°í, ºñÁ¤»óÀûÀÎ ÇÏÁß°ú ¸¶¸ð·Î ÀÎÇØ °üÀý ¿¬°ñÀÌ ´õ¿í ¾ÇÈ­µË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀº ÁÖ·Î »õ·Î¿î Ä¡·áÁ¦ ½ÃÀå °³¹ß Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ij³ª´Ùº¸°Ç¿¬±¸±â±¸(CIHR)´Â 2021³â°³ °ñ°üÀý¿° Ä¡·á¿¡ ´ëÇÑ Áß°£¿± Áٱ⼼Æ÷ÀÇ È¿´ÉÀ» Æò°¡ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá 60¸¸ ´Þ·¯ ±Ô¸ðÀÇ ÄÄÇ»ÅÍ Áö¿ø ¼³°è(CAD) ÇÁ·ÎÁ§Æ®¿¡ ÀÚ±ÝÀ» Áö¿øÇß½À´Ï´Ù. ÀÌ ¿¬±¸´Â °í°´ÀÌ ¼ÒÀ¯ÇÑ ÆÈ²ÞÄ¡ °üÀý¿° ¶Ç´Â °Å°ñ °ñ°üÀý¿°À» ¾Î°í ÀÖ´Â ¹Ý·Á°ßÀ» ´ë»óÀ¸·Î ¹«ÀÛÀ§ ÀÌÁß¸Í°Ë À§¾à´ëÁ¶ ÀÓ»ó½ÃÇèÀ» ½Ç½ÃÇÒ ¿¹Á¤ÀÌ´Ù(Ãâó: CIHR ÇÁ·ÎÁ§Æ® ÀÚ±Ý Áö¿ø). ÀÌ·¯ÇÑ ¿¬±¸ °á°ú¸¦ ÅëÇØ »õ·Î¿î Àç»ýÀÇ·áÀÇ °¡´É¼º¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ °í±Þ Ä¡·á ¿É¼ÇÀÌ ´Ã¾î³²¿¡ µû¶ó ´õ ¸¹Àº º¸È£ÀÚµéÀÌ ¼öÀÇ»çÀÇ µµ¿òÀ» ¹Þ¾Æ ¹Ý·Áµ¿¹°ÀÇ °üÀý¿°À» Àû±ØÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ´Â ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå ¿¹Ãø °¡´ÉÇÑ ¹Ì·¡¿¡ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀÏÀ» ÀÛ¼ºÇß½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀåÀÇ Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ¼­ºñ½º Á¦°ø Æ÷Æ®Æú¸®¿À
  • PEST ºÐ¼®
  • PORTERÀÇ »ê¾÷ ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå : µ¿¹° À¯Çüº°, 2020-2032³â

  • °³
  • °í¾çÀÌ
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå : ÀûÀÀÁõº°, 2020-2032³â

  • °ñ°üÀý¿°
  • ±âŸ °üÀý¿°

Á¦7Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå, Ä¡·áº°, 2020-2032³â

  • ¾àÁ¦
  • NSAIDs
  • ¸ð³ëŬ·Î³Î Ç×ü
  • ±âŸ ÀǾàǰ
  • º¸ÃæÁ¦
  • ±âŸ Ä¡·á¹ý

Á¦8Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

  • µ¿¹°º´¿ø¡¤Å¬¸®´Ð
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ½ºÅä¾î
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå, Áö¿ªº°, 2020-2032³â

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • Vetoquinol
  • NexGen Pharmaceuticals
  • Norbrook
  • Eltech K-Laser s.r.l
  • Zoetis
  • Virbac
  • Elanco
  • Boehringer Ingelheim International GmbH
  • Ceva
  • Dechra Pharmaceuticals PLC
  • Others Prominent Players

Á¦11Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA

Global Companion Animal Arthritis Market is estimated to be valued at USD 4.67 Bn in 2025 and is expected to reach USD 7.8 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 4.67 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.60% 2032 Value Projection: USD 7.8 Bn
Figure. Companion Animal Arthritis Market Share (%), By Region 2025
Companion Animal Arthritis Market - IMG1

Osteoarthritis (OA) is a common condition that affects dogs and cats. It is characterized as a low-grade inflammatory, progressive degenerative joint disease. OA results from degeneration and aberrant repair of articular cartilage in association with alterations in subchondral bone metabolism, osteophytosis, and synovial inflammation. In companion animals, OA is almost always secondary to an underlying abnormality, such as joint laxity, osteochondrosis, trauma, etc. It is a pathological process that includes joint capsule fibrosis and periosteal reactions, leading to an altered gait and range of motion. In turn, there is a deterioration of the musculoskeletal system and secondary joint stabilizers, resulting in further deterioration of articular cartilage due to abnormal loading and wear.

Market Dynamics:

The global companion animal arthritis market is mainly driven by the increasing development of novel therapeutics. For instance, the Canadian Institutes of Health Research (CIHR) funded a US$600,000 Computer-aided design (CAD) project launched in 2021 focused on evaluating the efficacy of mesenchymal stem cells for the treatment of osteoarthritis in dogs. The study involves a randomized, double-blinded, placebo-controlled clinical trial involving client-owned dogs with elbow or stifle osteoarthritis (source: CIHR project funding). Findings from these studies will provide valuable insights into the potential of new regenerative medicine options. Furthermore, the greater availability of advanced treatment choices will encourage more pet owners to actively manage their pet's arthritis with the help of veterinarians. This, in turn, will fuel ongoing expansion in the companion animal arthritis market beyond the foreseeable future.

Key features of the study:

  • This report provides in-depth analysis of the global companion animal arthritis market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global companion animal arthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Vetoquinol, NexGen Pharmaceuticals, Norbrook, Eltech K-Laser s.r.l, Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC .
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global companion animal arthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion animal arthritis market

Global Companion animal arthritis Market Detailed Segmentation:

  • By Animal Type
    • Dogs
    • Cats
    • Others
  • By Indication
    • Osteoarthritis
    • Other Arthritis
  • By Treatment
    • Medication
    • NSAIDs
    • Monoclonal Antibodies
    • Others Medications
    • Supplements
    • Other Treatment
  • By Distribution Channel
    • Veterinary Hospitals & Clinics
    • Retail Pharmacies
    • Online Stores
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles
    • Vetoquinol
    • NexGen Pharmaceuticals
    • Norbrook
    • Eltech K-Laser s.r.l
    • Zoetis
    • Virbac
    • Elanco
    • Boehringer Ingelheim International GmbH
    • Ceva
    • Dechra Pharmaceuticals PLC
    • Others Prominent Players .

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Companion Animal Arthritis Market, By Animal Type
    • Global Companion Animal Arthritis Market, By Treatment
    • Global Companion Animal Arthritis Market, By Indication
    • Global Companion Animal Arthritis Market, By Distribution Channel
    • Global Companion Animal Arthritis Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rising Concerns About Self-Image and Confidence
    • Side effects of treatment options
    • Untapped emerging markets
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Service offering Portfolio
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Pipeline Analysis

4. Global Companion Animal Arthritis Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Companion Animal Arthritis Market, By Animal Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Dogs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Cats
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Companion Animal Arthritis Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Osteoarthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other Arthritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Companion Animal Arthritis Market, By Treatment, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • NSAIDs
  • Monoclonal Antibodies
  • Others Medications
  • Supplements
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other Treatments
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Companion Animal Arthritis Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Veterinary Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Online Stores
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Companion Animal Arthritis Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Animal Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Vetoquinol
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • NexGen Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Norbrook
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Eltech K-Laser s.r.l
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Zoetis
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Virbac
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Elanco
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim International GmbH
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Ceva
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Dechra Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Others Prominent Players
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦